Delpharm, a CDMO headquartered in France, has entered into an agreement with BioNTech to manufacture the BNT 162b2 vaccine to prevent Coronavirus infection at its plant in Saint-Rémy-sur-Avre (Normandy).

Delpharm will begin manufacturing in April 2021 and will produce tens of millions of doses.

Stéphane Lepeu, Delpharm’s Chief Commercial Officer, said, “Delpharm is proud to be the first company selected to produce this vaccine in France.”

This agreement will enable Delpharm to recruit an additional 40 to 60 people at its Saint-Rémy-sur-Avre site.